The use of procalcitonin assays had little impact on antibiotic exposure in patients who presented to emergency departments (ED) with suspected lower respiratory tract infections, according to findings of the ProACT* trial presented at the recent sessions of the American Thoracic Society (ATS 2018).
Aclidinium bromide does not increase the risk of major adverse cardiac event (MACE) in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD) who also had significant cardiovascular (CV) risk factors, according to the phase IV ASCENT COPD* study presented at ATS 2018.
All-night continuous positive airway pressure (CPAP) treatment significantly reduced 24-hour (ie, daytime and nighttime) resting heart rate (HR) in patients with obstructive sleep apnoea (OSA) and prediabetes, according to a study presented at ATS 2018 held in San Diego, California, US.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.